ATR mutation
|
Solid Tumor
|
ATR mutation
|
Solid Tumor
|
Immunotherapy Sensitive: B - Late Trials
|
Immunotherapy Sensitive: B - Late Trials
|
ATR mutation
|
Gastroesophageal Junction Adenocarcinoma
|
ATR mutation
|
Gastroesophageal Junction Adenocarcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ATR mutation
|
Gastric Adenocarcinoma
|
ATR mutation
|
Gastric Adenocarcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ATR mutation
|
Colon Cancer
|
ATR mutation
|
Colon Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ATR mutation
|
HER2 Negative Breast Cancer
|
ATR mutation
|
HER2 Negative Breast Cancer
|
talazoparib Sensitive: C3 – Early Trials
|
talazoparib Sensitive: C3 – Early Trials
|
ATR mutation
|
CRC
|
ATR mutation
|
CRC
|
M6620 + SNB-101 Sensitive: D – Preclinical
|
M6620 + SNB-101 Sensitive: D – Preclinical
|
ATR mutation
|
CRC
|
ATR mutation
|
CRC
|
M6620 Sensitive: D – Preclinical
|
M6620 Sensitive: D – Preclinical
|
ATR mutation
|
CRC
|
ATR mutation
|
CRC
|
SNB-101 Sensitive: D – Preclinical
|
SNB-101 Sensitive: D – Preclinical
|